Felodipine extended-release tablets

This product is a dihydropyridine calcium channel antagonist (calcium channel blocker), which acts by reversibly competing for dihydropyridine binding sites, blocking the voltage-dependent Ca2 current of vascular smooth muscle and cultured rabbit atrial cells, and blocking K-induced rat portal vein contracture.

Chemical name: 2,6-dimethyl-4-(2,3-dichlorophenyl)-1,4-dihydro-3,5-pyridinedicarboxylic acid ethyl ester.

This product is a film-coated tablet, which appears white or off-white after removing the film coating.

Hypertension, angina pectoris.

Oral administration, dosage should be individualized. The medication should be taken in the morning, swallowed with water, and the tablets should not be broken, crushed or chewed. 1 Treatment of hypertension: It is recommended to take 5 mg once a day as the starting treatment dose, and the commonly used maintenance dose is 5 or 10 mg once a day. The dose can be reduced or increased according to the patient's response, or other antihypertensive drugs can be added. The dose adjustment interval is generally not less than 2 weeks. For some patients, such as elderly patients and patients with impaired liver function, 2.5 mg once a day may be sufficient. Doses exceeding 10 mg once a day are usually not required. 2 Treatment of angina pectoris: It is recommended to take 5 mg once a day as the starting treatment dose, and the commonly used maintenance dose is 5 or 10 mg once a day.

The most common adverse reaction of this product is mild to moderate ankle edema, which is caused by peripheral vasodilation and is dose-related. Experience from clinical trials shows that 2% of patients discontinued treatment due to ankle edema. Facial flushing, palpitations, dizziness and fatigue may occur when starting treatment or increasing the dose. These reactions are often short-lived. Occasionally, there are case reports of mental confusion and sleep disorders, but the connection with felodipine has not been clearly established. There are also reports that patients with gingivitis or periodontitis may experience gingival swelling after medication, but this can be avoided or reversed through dental care.

Patients with decompensated heart failure, acute myocardial infarction, unstable angina pectoris, and those who are allergic to felodipine or any of the ingredients in this product.

Precautions for children: There is limited experience with the use of this product in children. Precautions for pregnancy and lactation: 1. Pregnancy. There is currently a lack of relevant data on the use of felodipine in pregnant women. In view of the teratogenicity observed in animal studies, felodipine should not be used by pregnant women. The possibility of pregnancy must be ruled out when recommending the use of plenidomide. Calcium antagonists can inhibit uterine pseudocontractions, but there is no definitive evidence that felodipine can delay the birth of full-term pregnancy. Due to the redistribution of blood flow caused by peripheral vasodilation, there is a risk of fetal chloride deficiency and uterine hypoperfusion in hypotensive mothers. 2. Lactation. Felodipine can be secreted into breast milk. If the mother uses a therapeutic dose of felodipine, only a very small amount will be transferred to the child through breast milk. There is not enough experience in breastfeeding women receiving felodipine treatment to assess its risk to the infant. Therefore, felodipine is contraindicated during lactation. If it is believed that the medical benefits of continued treatment with felodipine outweigh the risks, breastfeeding should be considered. Precautions for the elderly: The blood concentration of this product increases with age, so the recommended initial dose for elderly patients (over 65 years old) is 2.5 mg per day, and the dose is adjusted according to individual response.

1. The simultaneous use of certain drugs that interfere with the cytochrome P4503A4 enzyme system may affect the blood concentration of dihydropyridine calcium antagonists such as felodipine. Hepatic enzyme inhibitors (such as cimetidine, erythromycin, itraconazole, ketoconazole and certain cypermethrin compounds present in grapefruit juice) may cause an increase in the blood concentration of felodipine. Hepatic enzyme inducers (such as phenytoin, carbamazepine, rifampicin, barbiturates) may cause a decrease in the blood concentration of felodipine. 2. Felodipine does not affect the blood concentration of cyclosporine. 3. Although felodipine has a high degree of plasma protein binding, it does not affect the binding degree of other high plasma protein binding drugs (such as warfarin). 4. No significant changes in the pharmacokinetic behavior of digoxin in patients with heart failure were observed when this product was used in combination with digoxin. 5. Other drugs such as indomethacin or spironolactone have no obvious interactions with this product.

Store below 25℃. Valid for 36 months.

10mg

36 months.

Shanxi Kangbao Biological Product Co., Ltd.

• Founded in:

  1995-05-18

• Address:

  No. 151, Beihuan West Street, Luzhou District, Changzhi City, Shanxi Province

• Tax NO.:

  91140000602311789X

• Registered Funds:

  69.2 million yuan

• Email:

  Log in to view